Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00003308




Registration number
NCT00003308
Ethics application status
Date submitted
1/11/1999
Date registered
27/01/2003
Date last updated
22/06/2023

Titles & IDs
Public title
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Scientific title
A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma
Secondary ID [1] 0 0
E-6397
Secondary ID [2] 0 0
CDR0000066255
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Cancer 0 0
Melanoma (Skin) 0 0
Metastatic Cancer 0 0
Ovarian Cancer 0 0
Sarcoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Cancer 0 0 0 0
Bone
Cancer 0 0 0 0
Brain
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - stereotactic radiosurgery

Treatment: Other: stereotactic radiosurgery
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed renal cell carcinoma, melanoma, or sarcoma with 1-3 newly
diagnosed intraparenchymal brain metastases based on contrast-enhanced MRI (CT scan
acceptable if patients have a medical contraindication to MRI)

- No lesion greater than 4.0 cm in diameter and, if multiple lesions are present, no
more than one greater than 3.0 cm in diameter

- No limitation on the extent of extracranial metastatic disease

- No metastases in the brain stem, midbrain, pons, or medulla

- No leptomeningeal metastases documented by MRI or CSF evaluation

- No metastases within 10 mm of optic nerve or chiasm

- No history of multiple liver metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- At least 3 months

Hematopoietic:

- Absolute neutrophil count greater than 1,000/mm^3

- Platelet count greater than 50,000/mm^3

- Hemoglobin greater than 8 g/dL

Hepatic:

- Not specified

Renal:

- Not specified

Other:

- No major medical illness

- No psychoses

- Not pregnant or nursing

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- Prior chemotherapy allowed

- Systemic chemotherapy may be continued at the discretion of investigator after
completion of radiosurgery

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior cranial radiotherapy

- Prior or concurrent radiotherapy to noncranial sites allowed

Surgery:

- No prior surgical resection for brain metastases

- Prior stereotactic biopsy for diagnostic purposes allowed
Minimum age
18 Years
Maximum age
120 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/02/1999
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Iowa
Country [2] 0 0
United States of America
State/province [2] 0 0
Michigan
Country [3] 0 0
United States of America
State/province [3] 0 0
Nebraska
Country [4] 0 0
United States of America
State/province [4] 0 0
New Mexico
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Pennsylvania
Country [7] 0 0
United States of America
State/province [7] 0 0
Wisconsin
Country [8] 0 0
Peru
State/province [8] 0 0
Lima
Country [9] 0 0
Puerto Rico
State/province [9] 0 0
San Juan

Funding & Sponsors
Primary sponsor type
Other
Name
Eastern Cooperative Oncology Group
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.

PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients
with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00003308
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Minesh P. Mehta, MD
Address 0 0
University of Wisconsin, Madison
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00003308